肯尼亚和美国的研究人员正在测试一种新的马疫苗, Kenya and U.S. researchers test a new horsepox-based mpox vaccine for safety and effectiveness.

肯尼亚医学研究所(KEMRI)和美国生物制药公司Tonix制药公司正在肯尼亚对TNX-801进行第一阶段临床试验。 TNX-801是一种以天花为基础的疫苗,旨在预防天花。 Kenya Medical Research Institute (KEMRI) and U.S. biopharmaceutical company Tonix Pharmaceuticals are conducting a Phase I clinical trial in Kenya for TNX-801, a horsepox-based vaccine designed to prevent mpox. 试验的目的是评价疫苗的安全性、耐受性和有效性。 The trial aims to evaluate the vaccine's safety, tolerability, and effectiveness. TNX-801被认为比老旧的天花疫苗更安全、更容易管理。卫生组织宣布,非洲和其他区域爆发天花,造成公共卫生紧急情况,此后研制了这种疫苗。 TNX-801 is considered safer and easier to administer than older smallpox vaccines, and its development follows the WHO's declaration of a Public Health Emergency due to mpox outbreaks in Africa and other regions.

November 13, 2024

7 文章